0
Deep & Emerging Tech·October 23, 2026·1 min read

US Eyes Investment Curbs Against China Biotech Firms

Share

Potential US curbs on investment into Chinese biotech extend the de-risking playbook beyond semis and AI into life sciences. Cross-border biotech startups and investors need to map ownership, data flows, and JV structures now—before rules harden around them.